Orlistat: Research, Dosing, and Where to Buy in 2026
A research-first profile for Orlistat (Alli, Xenical), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Orlistat is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, 2 attributed expert mentions, and 1 transcript dosing protocol for Orlistat, each linked to its source.
- Also indexed as Alli, Xenical.
- 1 aggregated dosing-protocol mention from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
- Evidence level in this entry is marked as fda_approved.
What is Orlistat?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Experts on background and overview · 2 cited mentions
"Steve reported that Xenical (orlistat) is used to inhibit fat absorption at 120 mg with each meal."
"there's a lipase inhibitor that you take that prevents the breakdown of fat in the intestinal tract"
What is Orlistat researched for?
Lipase inhibitor that blocks dietary fat absorption - used by Nile to quickly clear digestion.
Orlistat Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | Staying Dry On A Cut, Injectable Oral AAS, Sleep: GH Secretagogues... | 00:56:51 | Vigorous Steve reported using 120 mg of orlistat with each meal on cheat-meal days to inhibit dietary fat absorption (anecdotal). | anecdotal |
Where to Buy Orlistat in 2026
No tracked vendor recommendations for Orlistat yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
What Experts Say
1 expert across our source library discuss Orlistat. Each entry is that expert’s most context-rich mention: click to watch it at the exact timestamp in the original video. Quotes are also emitted as Schema.org Quotation JSON-LD for AI assistants.
-
“Steve reported that Xenical (orlistat) is used to inhibit fat absorption at 120 mg with each meal.”
See 1 more expert mention →
-
“there's a lipase inhibitor that you take that prevents the breakdown of fat in the intestinal tract”
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Orlistat. Each line links to the original source.
- "The absolute decrease in LFC in the orlistat group was 9.1% and 5.4% in the experimental diet group, both significantly higher than that in the control group (P < 0.05)." · Feng X et al, 2023 PubMed
- "The relative reduction in LFC was 30.2% in the experimental diet group, which was significantly higher than the 12.2% observed in the control group (P = 0.01)." · Feng X et al, 2023 PubMed
- "Compared with subjects who received placebo and a hypocaloric diet alone, weight loss of at least 5 to 10% of initial body weight was observed in a significantly larger number of subjects who were treated with orlistat plus a hypocaloric diet during the first year of treatment." · Wong N et al, 2000 PubMed
- "In clinical trials, orlistat (120 mg t.i.d.) in combination with life-style modification and a hypocaloric diet (30% of energy from fat) induced significantly more weight loss and improved health complications of obesity (diabetes, hypertension, hyperlipidaemia) compared to patients treated with diet alone." · Ballinger A et al, 2000 PubMed
- "Side effects related to fat malabsorption, occurred in more than 20% of subjects during the first year of treatment and included oily faecal spotting, abdominal pain, flatus with discharge and fatty/oily stool." · Ballinger A et al, 2000 PubMed
- "Obese patients who were maintained on a hypocaloric diet and who received orlistat 360 mg/day for 12 weeks lost a significantly greater percentage of bodyweight than placebo recipients (5 vs 3.5%)." · McNeely W et al, 1998 PubMed
- "A greater proportion of orlistat than placebo recipients lost > 5% or > 10% of their initial bodyweight in 1- and 2-year studies." · McNeely W et al, 1998 PubMed
- "From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p<0.001] from randomisation to the end of year 1)." · Sjöström L et al, 1998 PubMed
Research and Studies
8 PubMed-indexed papers reference Orlistat. Top 8 shown.
Legal Status
Orlistat is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Orlistat FDA-approved?
Orlistat is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Orlistat?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Orlistat?
8 PubMed-indexed paper(s) reference Orlistat in our current research feed. See the Research and Studies section above for citations.